What maintenance asthma medication is recommended during pregnancy?

Maintenance Asthma Medication in Pregnancy

For pregnant women with persistent asthma requiring maintenance therapy, inhaled corticosteroids (ICS) are the preferred treatment, with budesonide being the specific ICS of choice due to the most extensive safety data in pregnancy. 1

Treatment Algorithm by Asthma Severity

Mild Persistent Asthma (Step 2)

• First-line: Low-dose inhaled budesonide daily
• The preference for budesonide is based on reassuring pregnancy-specific data showing no increased risk of adverse perinatal outcomes 1
• Important caveat: Other ICS (beclomethasone, fluticasone) are NOT unsafe—if a woman was well-controlled on a different ICS before pregnancy, continue it rather than switching, as changing formulations may jeopardize asthma control 1

Alternative options (not preferred):

• Cromolyn: excellent safety profile but limited effectiveness compared to ICS
• Leukotriene receptor antagonists: only if asthma was successfully controlled pre-pregnancy; minimal pregnancy data but reassuring animal studies
• Theophylline: requires careful dose titration and monitoring (target 5-12 mcg/mL) due to toxicity risk 1

Moderate Persistent Asthma (Step 3)

Two equally preferred options:

1. Low-dose ICS + long-acting beta-2 agonist (LABA)
2. Medium-dose ICS alone

• For combination therapy, salmeterol may be preferred over formoterol as it has been available longer in the U.S., though both have similar safety profiles to albuterol 1
• Recent data shows SABA + ICS + LABA regimens improve lung function and reduce inflammation across gestation 2

All Severity Levels

• Quick-relief medication: Albuterol is the preferred short-acting beta-2 agonist—extensive safety data with no evidence of fetal injury 1

Critical Clinical Principles

The fundamental principle: It is safer for pregnant women to be treated with asthma medications than to have uncontrolled asthma symptoms and exacerbations. Inadequate asthma control poses greater risk to the fetus than asthma medications 1

Common Pitfalls to Avoid

1. Medication discontinuation: Inadvertent interruption of maintenance medication is one of the most common factors associated with exacerbations during pregnancy 3

2. Undertreatment due to safety concerns: Recent evidence confirms that ICS use during pregnancy actually decreases odds of preterm birth (OR: 0.62) and NICU admission (OR: 0.66) 4

3. Switching medications unnecessarily: If pre-pregnancy control was good on a specific ICS, maintain that regimen rather than switching to budesonide 1

4. Inadequate monitoring: Women on intensive regimens (SABA + ICS + LABA) have higher risk of severe exacerbations during early-to-mid pregnancy despite better lung function, requiring closer surveillance 2

Monitoring Recommendations

• Peak expiratory flow (PEF) monitoring is generally sufficient for routine follow-up
• Serial ultrasounds starting at 32 weeks for women with suboptimally controlled or moderate-to-severe asthma 1
• Patients should monitor fetal activity 1

Supporting Evidence Quality

The 2020 ERS/TSANZ guidelines 5 corroborate the NAEPP recommendations, confirming budesonide and beclomethasone as preferred ICS with the most pregnancy data. The most recent research (2024-2025) consistently supports continuing maintenance medications throughout pregnancy 3, 6, 4, with one 2024 study demonstrating that ICS use specifically reduces adverse neonatal outcomes 4.

The evidence strongly favors aggressive asthma control over medication avoidance—maternal hypoxia from uncontrolled asthma poses far greater fetal risk than any currently used asthma medication.